Kwangdong Pharmaceutical Joins the 'KRW 1 Trillion Club' for the First Time with KRW 1.6 Trillion in Revenue

Renewal of Samdasoo Contract and Introduction of New Drugs
Expanding the Business Portfolio

Kwangdong Pharmaceutical announced on March 26 that it held its 53rd Annual General Meeting of Shareholders in Gwacheon, Gyeonggi Province, and approved the agenda items as originally proposed, including the approval of financial statements, appointment of directors, and amendments to the articles of incorporation.

On a separate basis, the company’s revenue last year reached KRW 1.011 trillion, surpassing KRW 1 trillion for the first time since its founding. On a consolidated basis, revenue was KRW 1.6595 trillion. Operating profit on a separate basis was approximately KRW 30.6 billion.

The company highlighted the renewal of its sales consignment contract for Jeju Samdasoo and the securing of new drug pipelines as major achievements. It also signed an exclusive domestic contract for the retinitis pigmentosa treatment candidate 'OCU400.'

This shareholders’ meeting also included measures to improve corporate governance, such as formalizing the independent director system and establishing new committees through amendments to the articles of incorporation.

Park Sangyoung, CEO of Kwangdong Pharmaceutical, stated, "The year 2026 will be a crucial turning point as we begin to fully realize the synergies from relocating to our new headquarters in Gwacheon. We will continue to identify business opportunities that generate both external growth and profitability, as well as future value, in order to maximize shareholder value."